| 张艳.归逍方加减联合人工周期治疗肾虚肝郁证型卵巢早衰闭经 49例观察[J].安徽医药,2022,26(1):192-196. |
| 归逍方加减联合人工周期治疗肾虚肝郁证型卵巢早衰闭经 49例观察 |
| Observation on 49 cases of ovarian premature aging and amenorrhea with kidney deficiency and liver stagnation syndrome treated by Guixiaofang addition and subtraction combined with artificial cycle |
| |
| DOI：10.3969/j.issn.1009-6469.2022.01.044 |
| 中文关键词: 原发性卵巢功能不全 黄体生成素 卵泡刺激素 归逍方 人工周期疗法 卵巢早衰 闭经 肾虚肝郁证 |
| 英文关键词: Primary ovarian insufficiency Luteinizing hormone Follicle stimulating hormone Guixiaofang Artificial cycle therapy Premature ovarian failure Amenorrhea Kidney deficiency liver stagnation syndrome |
| 基金项目: |
|
| 摘要点击次数: 1836 |
| 全文下载次数: 642 |
| 中文摘要: |
| 目的探究观察归逍方加减联合人工周期对卵巢早衰闭经(肾虚肝郁证)的治疗效果。方法将 2017年 8月至 2019年 1月安阳市人民医院收治的 96例卵巢早衰闭经(肾虚肝郁证)病人作为研究对象，采用随机数字表法分为对照组 47例和观察组 49例。观察组病人采用归逍方加减联合人工周期进行治疗，对照组病人进行人工周期治疗。对比两组病人治疗前后的症状积分、治疗前后的性激素水平、治疗前后卵巢体积与窦卵泡数、临床疗效分布及总有效率，不良反应发生情况。结果两组病人治疗前症状积分均相近( P>0.05)且治疗后两组症状积分均下降［对照组:(15.96±3.01)分比( 7.97±1.57)分，(8.86±1.86)分比( 5.97±1.17)分，(24.82±4.43)分13.94±2.29)分；观察组:(16.18±3.15)分比( 5.51±1.05)分，(8.95±1.58)分比( 4.15± 比(0.88)分，(25.13±4.52)分比( 9.66±1.87)分］(P<0.05)，观察组均低于对照组(P<0.05)；治疗后两组病人的黄体生成素( LH)、卵泡刺激素( FSH)水平比治疗前均降低［对照组:(47.72±9.51)IU/L比( 28.42±5.43)IU/L，(66.23±13.22)IU/L比( 36.91±7.13)IU/L；观察组:(45.53±9.81)IU/L比( 21.51±4.12)IU/L，(64.11±13.12)IU/L比( 27.02±5.31)IU/L］(P<0.05)，同时观察组均低于对照组( P< 0.05)两组病人的雌激素( E2)水平比治疗前均升高［对照组:(44.30±8.40)ng/L比( 77.50±12.37)ng/L；观察组:(46.30±9.39)ng/L比( 83.3，6±13.25)ng/L］(P<0.05)，同时观察组均高于对照；治疗后两组病人的卵巢体积比治疗前均变大、窦卵泡数比治疗前均增多［对照组:(9.02±1.23)cm3比( 11.03±2.14)cm3，(2.74±0.46)个比( 3.41±0.69)个；观察组:(9.11±1.82)cm3比( 13.12±2.59)cm3，(2.87±0.53)个比(5.68±1.12)个］(P<0.05)且观察组各指标变化幅度均大于对照组(P<0.05)；观察组病人治疗效果等级分布与对照组比较差异有统计学意义( P<0.05)察组的治疗总有效率是 85.71％，比对照组的 61.70％高( P<0.05)；观察组不良反应发生率为 4.44%与对照组的 4.26%相P>0.05)。结论归逍方加减联合人工周期治疗卵巢早衰闭经(肾虚肝郁证)能显且观，近(，著控制症状，改善血清 FSH、LH和 E2水平、促进卵巢体积增大与窦卵泡数增多，且疗效和安全性良好。 |
| 英文摘要: |
| Objective To investigate the therapeutic effect of Guixiaofang addition and subtraction combined with artificial cycle onovarian premature aging obstruction (kidney deficiency and liver stagnation syndrome).Methods A total of 96 patients with ovarianpremature aging obstruction (kidney deficiency and liver stagnation syndrome) admitted to Anyang People's Hospital from August 2017to January 2019 were randomly divided into control group (47 cases) and 49 observation group (49 cases) by a random digital table. Pa-tients in the observation group were treated with Guixiaofang plus artificial reduction, and the control group was treated with artificialcycle. The symptom scores before and after treatment, the levels of sex hormones before and after treatment, ovarian volume and antralfollicle number before and after treatment, the clinical efficacy distributions and total effective rates, the incidence of adverse reactionswere compared between the two groups.Results The symptom scores of the two groups were similar before treatment (P>0.05), and the symptom scores of the two groups were decreased after treatment [control group: (15.96±3.01) scores vs. (7.97±1.57) scores, (8.86±1.86) scores vs. (5.97±1.17) scores, (24.82±4.43) scores vs. (13.94±2.29) scores; observation group: (16.18±3.15) scores vs. (5.51±1.05) scores, (8.95±1.58) scores vs. (4.15±0.88) scores, (25.13±4.52) scores vs. (9.66±1.87) scores] (P<0.05), and those in the observation group were lower than those in the control group (P<0.05),The levels of luteinizing hormone (LH), follicle stimulating hormone (FSH) inthe two groups were lower than those before treatment [control group: (47.72±9.51) IU/L vs. (28.42±5.43) IU/L, (66.23±13.22) IU/L vs. (36.91±7.13) IU/L; observation group: (45.53±9.81) IU/L vs. (21.51±4.12) IU/L, (64.11±13.12) IU/L vs. (27.02±5.31) IU/L] (P<0.05), |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
